Dementia is an umbrella term for a progressive decline in thinking, memory, and reasoning severe enough to disrupt daily life. Alzheimer’s disease (AD) is the most common cause—about 60–80% of cases—but other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Mild cognitive impairment (MCI) represents “beyond-normal” forgetfulness with preserved independence and can precede dementia. Getting the diagnosis right matters: it guides treatment and support and can affect eligibility for clinical trials.

Clinicians diagnose dementia by confirming decline in at least two cognitive or behavioral domains (e.g., memory, language, executive function, mood/personality) using history from patients and families plus brief cognitive tests and a focused exam to flag specific etiologies. AD is identified by a gradual, steadily worsening pattern. Assessments may be supplemented by biomarkers (PET imaging or cerebrospinal fluid tests for amyloid and tau), though these are invasive/costly and not universally used; simpler blood tests are in development. While there’s no cure, symptomatic therapies and emerging disease-modifying drugs (some granted accelerated FDA approval) may slow progression, underscoring the value of early, accurate diagnosis and coordinated support for patients and caregivers.

Reference: Fifield K. Dementia vs. Alzheimer’s: Which Is It? How to understand the difference — and why it matters. AARP. Published June 15, 2020. Updated May 09, 2023. https://www.aarp.org/health/conditions-treatments/difference-between-dementia-alzheimers/ 

Dementia is a progressive decline in one or more cognitive domains with loss of everyday function. Alzheimer disease (AD) is the most common cause, but vascular, Lewy body, frontotemporal, Parkinson’s disease dementia, prion disorders, HIV, Huntington disease, TBI, substances, and mixed etiologies also occur. Pathology varies (e.g., amyloid/tau in AD; α-synuclein in Lewy/Parkinson; ischemia in vascular dementia). Evaluation relies on history from patients and caregivers, assessment of function, bedside cognitive tests (MMSE, MoCA, Mini-Cog, etc.), and targeted labs to exclude reversible causes (B12, TSH, infections, metabolic issues), with MRI when atypical, early, or rapidly progressive. Hallmark clinical patterns (e.g., visual hallucinations and fluctuating attention in Lewy body; behavioral/language variants in FTD; stepwise decline in vascular) help narrow the diagnosis.

Management is multifaceted: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine offer modest symptomatic benefit. Aducanumab has controversial approval based on amyloid reduction without clear clinical benefit. Non-drug strategies—exercise, sleep optimization, hearing/vision treatment, cognitive and social engagement, caregiver training—are essential, alongside treatment of behavioral symptoms when needed. Differential diagnoses include delirium, depression, MCI, medication effects, structural lesions, and vitamin/thyroid deficiencies. Prognosis is generally poor with high 1- and 5-year mortality. Complications include malnutrition, falls/fractures, infections, dysphagia, neuropsychiatric symptoms, and safety risks (driving, wandering). Best outcomes depend on coordinated interprofessional care (physicians, nurses, pharmacists, social workers), regular safety reviews, caregiver support, and individualized care plans to reduce hospitalizations and improve quality of life.

Reference: Emmady PD, Schoo C, Tadi P. Major Neurocognitive Disorder (Dementia). 2022 Nov 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491376.

Researchers developed an international core outcome set (COS) to standardize how trials in long-term care (LTC) measure delirium prevention and treatment, addressing widespread heterogeneity that has impeded evidence synthesis and clear guidance. Registered with the COMET initiative, the team used a rigorous, multi-step process: qualitative interviews with family members and LTC staff who had first-hand experience of delirium; a modified, two-round Delphi survey to rate and re-rate priorities; and virtual consensus meetings using nominal group technique to resolve disagreements. Item generation from 18 interviews surfaced 22 delirium-specific and 32 additional outcomes. After reduction and integration with a prior systematic review, 43 outcomes advanced to formal consensus. In total, 169 stakeholders from 12 countries—121 healthcare professionals (72%), 24 researchers (14%), and 24 family members/people with lived experience (14%)—participated, ensuring both clinical relevance and patient-centered perspectives.

From this process, six outcomes were identified as essential and recommended for inclusion in all LTC delirium trials: delirium occurrence, delirium-related distress, delirium severity, cognition (including memory), hospital admission, and mortality. Together, these domains capture symptom burden, functional impact, and hard endpoints that matter to patients, families, and systems, while remaining feasible to measure across diverse LTC settings and study designs. Adoption of this COS—endorsed by the American Delirium Society and the European and Australasian Delirium Associations—should improve comparability across studies, enable higher-quality meta-analyses, reduce research waste, and ultimately accelerate the translation of trial findings into consistent, actionable care for older adults in LTC.

Reference: Russell G, Rana N, Reilly ST, et al. Core outcome set for studies evaluating interventions to prevent or treat delirium in long-term care older residents: international key stakeholder informed consensus study. Age Ageing. 2024 Oct 1;53(10):afae227. doi: 10.1093/ageing/afae227. PMID: 39396912; PMCID: PMC11471312.